Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 7, pp 1814–1827 | Cite as

The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies

  • Emily Z. Keung
  • Esosa U. Ukponmwan
  • Alexandria P. Cogdill
  • Jennifer A. Wargo
Melanomas

Abstract

Unprecedented advances in the treatment of cancer have occurred through the use of immunotherapy, with several agents currently approved by the Food and Drug Administration (FDA) for the treatment of widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory molecules on the surface of T cells, resulting in their activation and propagation of an immune response. Treatment with these agents may re-invigorate anti-tumor immunity, resulting in therapeutic responses, and use of these agents currently is being studied in the adjuvant setting. Additionally, a strong rationale exists for their use in the neoadjuvant setting for high-risk resectable disease (e.g., regional nodal disease in the case of melanoma). This rationale is based on the relatively high risk of relapse for these patients, as well as on scientific evidence suggesting that long-term immunologic memory and tumor control may be superior in the setting of treatment for an intact tumor (i.e., neoadjuvant therapy) as opposed to treatment in the setting of micrometastatic disease (e.g., adjuvant treatment). The potential advantages of this approach and the current landscape for neoadjuvant immune checkpoint blockade is discussed in this report, as well as caveats that should be considered by clinicians contemplating this strategy.

Notes

Disclosures

Jennifer A. Wargo is a co-founder and scientific advisor to Microbiome DX, received clinical trial support from Roche-Genentech, GSK, BMS, and Novartis; is an advisory board member for Roche-Genentech, GSK, and Novartis; and is on the speaker’s bureau for Imedex, Dava, Omniprex, and Illumina.

References

  1. 1.
    Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19:1021–34.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12:130–46.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42:363–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brunet JF, Denizot F, Luciani MF, et al. (1987) A new member of the immunoglobulin superfamily–CTLA-4. Nature. 328:267–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Walunas TL, Lenschow DJ, Bakker CY, et al. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. . 1994. 1: 405–413.CrossRefPubMedGoogle Scholar
  8. 8.
    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459–65.CrossRefPubMedGoogle Scholar
  9. 9.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.CrossRefPubMedGoogle Scholar
  11. 11.
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Postow M, Callahan M, Wolchok J. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T cell activation. Oncologist. 2008;13(Suppl 4):2–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: Pd-1/pd-l1 blockade in melanoma. Clin Ther. 2015;37:764–82.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vanpouille-Box C, Lhuillier C, Bezu L, et al. Trial watch: immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017;6:e1373237.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Robert C, Ribas A, Wolchok J. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.CrossRefPubMedGoogle Scholar
  20. 20.
    Le D, Uram J, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22.CrossRefPubMedGoogle Scholar
  23. 23.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Balar AV, Catellano D, O’Donnell PH, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population (abstract). J Clin Oncol. 2017;35(Suppl):284.CrossRefGoogle Scholar
  25. 25.
    Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Balar A V., Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.CrossRefPubMedGoogle Scholar
  27. 27.
    Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non–small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46.CrossRefPubMedGoogle Scholar
  28. 28.
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med. 2015;373:1627–39.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med. 2015;373:123–35.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018–28.CrossRefPubMedGoogle Scholar
  31. 31.
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–508.CrossRefPubMedGoogle Scholar
  33. 33.
    Alexander W. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects: new drugs, indications, and combinations continue to emerge. Pharm Ther 2016;41:185–91.Google Scholar
  34. 34.
    Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–47.CrossRefPubMedGoogle Scholar
  36. 36.
    Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.CrossRefPubMedGoogle Scholar
  38. 38.
    Grossman HB, Natale RB, Tangen CM, et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66CrossRefPubMedGoogle Scholar
  39. 39.
    Fisher B, Brown A. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel. J Clin Oncol. 1997;15:2483–93.CrossRefPubMedGoogle Scholar
  40. 40.
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.CrossRefPubMedGoogle Scholar
  41. 41.
    Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRefGoogle Scholar
  42. 42.
    Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Salvador-Coloma C, Cohen E. Multidisciplinary care of laryngeal cancer. J Oncol Pract. 2016;12:717–24.CrossRefPubMedGoogle Scholar
  45. 45.
    Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long–term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Franco P, Arcadipane F, Strignano P, et al. Preoperative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol. 2017;34:1–7.CrossRefGoogle Scholar
  47. 47.
    Anderegg MCJ, van der Sluis PC, Ruurda JP, et al. Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2017. 24:2282-2290CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Noordman BJ, van Klaveren D, van Berge Henegouwen MI, et al. Impact of surgical approach on long-term survival in esophageal adenocarcinoma patients with or without neoadjuvant chemoradiotherapy. Ann Surg. 2017;  https://doi.org/10.1097/SLA.0000000000002240.CrossRefGoogle Scholar
  49. 49.
    van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMedGoogle Scholar
  50. 50.
    Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l. J Clin Oncol. 2010;28:859–65.CrossRefPubMedGoogle Scholar
  51. 51.
    Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Cancer Netw. 2014;12:513–9.CrossRefGoogle Scholar
  52. 52.
    Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL. Making the most of cancer surgery with neoadjuvant immunotherapy. Cancer Discov. 2016;6:1312–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol. 2013;31:237–50.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6(12): 1382-1399CrossRefPubMedGoogle Scholar
  55. 55.
    van Zeijl MCT, van den Eertwegh AJ, Haanen JB, Wouters MWJM. (Neo)adjuvant systemic therapy for melanoma. Eur J Surg Oncol. 2017;43:534–43.CrossRefPubMedGoogle Scholar
  56. 56.
    Chen P-L, Roh W, Reuben A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–37.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Emily Z. Keung
    • 1
  • Esosa U. Ukponmwan
    • 1
  • Alexandria P. Cogdill
    • 1
  • Jennifer A. Wargo
    • 1
  1. 1.Department of Surgical Oncology and Genomic MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations